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Local Anesthetics
as Pain Therapy
in Horses
Thomas J. Doherty, MVB, MSc*, M. Reza Seddighi, DVM, PhD
Despite the introduction of new drugs and techniques, it is recognized that many
human patients experience moderate to severe pain postoperatively. In addition, it
is now understood that postoperative pain can result in undesirable sequelae, such
as chronic pain.1 Although anthropomorphizing can lead to erroneous conclusions,
it appears reasonable to assume that horses may also develop chronic pain after an
episode of acute postoperative pain, and a recent study indicates that acute laminitis
may lead to neuropathic pain.2 Presently, the arsenal of analgesic drugs for use in the
equine patient is limited. Systemic use of opioids is restricted because of adverse
effects such as behavioral changes3 and ileus.4 The epidural administration of local
anesthetics is mainly limited to pain relief of the perineum because of the need to
maintain motor function, although morphine can be administered by this route without
causing motor block. However, many clinicians see epidural drug administration as
invasive and carrying the risk of infection. Consequently, equine practitioners continue
to rely heavily on less efficacious drugs, primarily nonsteroidal anti-inflammatory
drugs, for pain control. Thus, there is a need for safe and inexpensive alternative
pain therapies for horses.
Studies in human patients and laboratory animals have demonstrated that systemi-
cally administered local anesthetics, such as lidocaine and its congener mexiletine,
can reduce the intensity of postoperative and neuropathic pain, although the mecha-
nisms of lidocaine’s actions are uncertain. Mexiletine is rarely used clinically, primarily
because it has significant side effects. Recent studies indicate that systemic lidocaine
mayhavepotential as ananalgesic andas a supplement to general anesthesia in horses.
HISTORICAL PERSPECTIVE ON THE SYSTEMIC USE OF LOCAL ANESTHETICS
The intravenous (IV) administration of the local anesthetic procaine, for analgesic
purposes, was initially described by Gordon in 1943,5 and further reports on its use
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in human patients followed.6,7 Lidocaine (lignocaine) is an amide local anesthetic that
is primarily used systemically as an antiarrhythmic drug; however, the use of IV lido-
caine for anesthetic and analgesic purposes was first reported over 50 years ago.8,9
In 1954, De Clive-Lowe and colleagues10 described their experiences with the admin-
istration of lidocaine in association with succinylcholine for general anesthesia in 1,000
human patients. It was later reported that the incidence of postoperative pain was
significantly less in patients that were administered lidocaine perioperatively and,
surprisingly, the analgesic effects were still evident on the third postoperative day.11
In spite of those early clinical studies demonstrating the anesthetic and analgesics
effects of IV lidocaine, there was no further interest in the topic for over 30 years,
presumably due to concerns of toxicity.
REDISCOVERY OF LIDOCAINE’S ANTINOCICEPTIVE EFFECTS
Renewed interest in the systemic administration of local anesthetics began in 1986,
when it was demonstrated that intra-abdominal instillation of bupivacaine decreased
the duration of postoperative colonic ileus in human patients.12 This research was
soon followed by a study that demonstrated the efficacy of IV lidocaine in decreasing
the duration of colonic stasis.13 Importantly, these studies showed that local anes-
thetics were efficacious at blood concentrations less than those considered to be
toxic; however, it is important to note that bupivacaine is not administered intrave-
nously because of its narrow therapeutic index.
The systemic administration of lidocaine for neuropathic pain has been the focus of
numerous studies,14,15 but the efficacy of lidocaine for the treatment of acute postop-
erative pain has gained attention of late. The analgesic effects of sodium (Na1) channel
blockers, such as lidocaine and mexiletine, have been demonstrated in studies in
rats16,17 and human volunteers.18,19 In human patients, IV lidocaine decreases post-
operative pain,18,20 is antihyperalgesic21 and anti-inflammatory,22 improves bowel
function postoperatively,23 and facilitates rehabilitation.24
Although it was initially established that IV lidocaine has analgesic effects in patients
with chronic neuropathic pain14,15 and is efficacious for the treatment of visceral
pain,25 the results of its efficacy in postoperative pain were conflicting. It is now under-
stood that differences in study findings are related to the timing of the lidocaine admin-
istration, and perhaps the dose of lidocaine administered and the type of noxious
stimulus. The intraoperative administration of large doses of lidocaine resulted in anal-
gesia and morphine-sparing effects.10,11 Intraoperative administration of lidocaine,
followed by a constant infusion for 24 hours postoperatively, resulted in significant
analgesia on the first and second postoperative day.26 In contrast to the aforemen-
tioned findings, administering a small dose of lidocaine, by infusion, in the postoper-
ative period did not produce analgesic effects.27,28
ORIGINS OF POSTOPERATIVE PAIN
Current understandingof painmechanismshasprogressed from theCartesian concept
that pain resulted from the direct transmission from peripheral receptors and fibers, via
the spinal cord, to a pain center in the brain. It is now understood that nociceptive input
is transmitted to the spinal cord, or specific cranial nerves, bymyelinated Ad and unmy-
elinatedC-fibers. The signal crosses thesynaptic junction in thedorsal hornof the spinal
cord via a series of chemical interactions before being transmitted by nociceptive-
specific or nonspecific wide dynamic range (WDR) neurons.
It is recognized that tissue injury may induce changes in the responsiveness of the
nociceptive system by causing peripheral and central sensitization.29 Generally,
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postoperative pain is believed to result from the interaction of three sources: (1) trauma
at the surgical site, which generates impulses in peripheral neurons; (2) peripheral
sensitization of nerve fibers at the surgical site due to the effects of inflammatory medi-
ators; and (3) central sensitization of the spinal cord subsequent to prolonged barrage
from nociceptive inputs. Although the trauma of incision and tissue manipulation acti-
vates central pathways implicated in sensitization, its influencemay be restricted to the
intraoperative period.30 It is currently understood that local anesthetics can be used
perioperatively to affect all three aforementioned sources of postoperative pain.
Peripheral sensitization involves (1) lowering of the response threshold in primary
afferent fibers, (2) an increase in response magnitude to suprathreshold stimuli, (3)
an increase in spontaneous activity, and (4) an increase in receptive field size.29
Decrease in tissue pH after surgical incision may also contribute to postoperative
pain and hyperalgesia.31 In addition, inflammatory mediators and the increased
temperature at the surgical site increase the activity of the transient receptor potential
vanilloid type 1 (TRPV1) receptor, resulting in the generation of action potentials that
may be perceived as pain.32 Neuronal excitability is amplified by chemokines and
cytokines, such as tumor necrosis factor a (TNF-a), interleukin (IL)-6, and prosta-
glandin E2 (PGE2), which, together with nerve growth factor, increases the expression
or activity of voltage-gated Na1 channels (VGSCs).33
In central sensitization there is a decrease in the pain threshold as a result of expo-
sure to excessive and prolonged nociceptive input altering the responsiveness of the
central nervous system (CNS).34 Thus, after development of central sensitization, an
innocuous stimulus is perceived as noxious.35 Secondary hyperalgesia, another
consequence of central sensitization, is an exaggerated response to stimuli applied
to undamaged tissue surrounding the site of injury.36 The process of central sensitiza-
tion involves a number of neurotransmitters and receptors including the N-methyl-D-
aspartate (NMDA) receptor.
The idea that inhalational anesthesiadoesnot protect against central sensitizationwas
proposedbyCrile37 in 1913.He claimed that patientswho had regional anesthesia of the
surgical site, in addition to inhalational anesthesia, experienced a reduction in postoper-
ative pain. This concept of preemptive analgesia was reintroduced in 1983 by Woolf,38
who provided evidence, based on animal studies, to support Crile’s observations.
MECHANISMS OF LIDOCAINE-INDUCED ANTINOCICEPTION
The mechanisms by which systemic lidocaine suppresses postoperative pain are
uncertain; however, a number of mechanisms have been proposed for its antinocicep-
tive effect (Box 1). Local anesthetics were initially considered to block only Na1 chan-
nels; however, there is an increasing body of evidence that these drugs also modulate
a wide range of ion channels, receptors, and nociceptive pathways in the CNS. Inter-
estingly, some of these effects occur at concentrations of local anesthetic much less
than those required for Na1 channel blockade.22 At clinically relevant blood concen-
trations of lidocaine, there is little or no effect on impulse conduction in uninjured
peripheral nerves. The plasma concentration (2-5mg/mL) of lidocaine that is efficacious
in alleviating pain is profoundly less than what is required to block electrically evoked
peripheral nerve conduction in nociceptive C and Ad fibers, as this would require
plasma concentrations of approximately 250mg/mL.39
Action at Sodium Channels
VGSCs transmit electrical signals along sensory neurons to the CNS by generation of
rapid action potentials. VGSCs are transmembrane proteinswith gated pores. Opening
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and closing of these pores is controlled by changes in transmembrane voltage gradi-
ents.40 Lidocaine binds to a receptor site within the a-subunit of the channel, thereby
blocking Na1 conduction and preventing the generation of an action potential.41
Interaction of lidocaine with sodium channels
Lidocaine is aweakbase and is available commercially as a salt. The salt formdissolves
in an aqueous solution into the nonionized (lipid soluble) and ionized (hydrophilic) forms.
The nonionized form of lidocaine crosses the axonal membranemore readily, becomes
protonated (Fig. 1), and then attaches to the binding site for local anesthetics, located
on the inside of the sodiumchannel,42,43 resulting in blockadeof sodium transfer across
thechannel. The ionizationconstant (pKa) of lidocaine is 7.9and, at physiologicpH (7.4),
79%of lidocaine exists in the ionized form.44 Thus, if the pHof the solutionwas closer to
the pKa, more of the nonionized form would be present, and the onset of nerve block
would bemore rapid. Sodiumbicarbonate is sometimes added to the lidocaine solution
to increase pH and, thereby, decrease the onset time and increase the duration of the
nerve block,45 in addition to decreasing pain on injection.46 However, there is no
evidence that the efficacy of systemically administered lidocaine is decreased by the
magnitude of pH change that might occur clinically; therefore, concurrent administra-
tion of sodium bicarbonate to acidotic animals cannot be recommended for the
purpose of increasing the efficacy of lidocaine.
Box 1
Reported effects of systemic lidocaine
Antinociceptive and minimum alveolar concentration-sparing mechanisms
Blockade of sodium channels
Blockade of calcium channels
Blockade of potassium channels
Blockade of presynaptic muscarinic receptors
Blockade or activation of transient receptor potential vanilloid type 1 receptors
Blockade of N-methyl-D-aspartate receptors
Activation of g-aminobutyric acid receptors
Activation of glycine receptors
Anti-inflammatory mechanisms
Inhibition of sequestration, migration, and activation of polymorphonuclear cells (PMNs).
Inhibition of PMN adherence to endothelial cells
Inhibition of Na1– H1 exchanger in PMNs
Suppression of histamine release from mast cells
Inhibition of nuclear factor kB
Decrease in chemotactic factors and cytokines
Decrease in albumin extravasation and microvascular permeability
Inhibition of sensory neurons with resultant decreases in release of substance P
Decrease in release of proinflammatory lipoxygenase products
Inhibition of the release of toxic oxygen metabolites
Decreased expression of inducible nitric oxide synthase
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Sodium channel subtypes
There are at least nine different VGSC subtypes in the nervous system and numerous
sensory neuronal channels have been implicated in pain mechanisms. The various
Na1 channel subtypes are encoded by different genes and changes in gene expres-
sion, resulting in upregulation of channels, may occur following tissue injury.47 VGSCs
subtypes Nav1.8 and Nav1.9 have been identified in nociceptive dorsal root ganglion
(DRG) neurons.48 The subtype Nav1.7 is considered to play a crucial role in nocicep-
tion because humans lacking functional Nav1.7 channels are insensitive to noxious
stimuli49 and a Nav1.7 knockout mouse model has deficits in response to inflammatory
stimuli.50 Although Nav1.3 is not normally expressed in adult sensory neurons, its
expression is upregulated as a consequence of chronic inflammation or nerve injury.51
Blockade of ectopic discharges
Under physiologic conditions, primary afferent neuronal inputs, which encode noci-
ceptive information from the periphery to the spinal cord, are generated only after
stimulation of peripheral receptors by chemical, heat, mechanical stimuli, or a combi-
nation thereof. However, injury to a peripheral nerve can cause a primary afferent input
to be generated spontaneously without activation of peripheral receptors. These
spontaneous discharges are often referred to as ectopic discharges. Ectopic
discharges in injured nerves result primarily from the activation of Na1 channels,52
and studies in numerous animal preparations indicate that the systemic administration
of lidocaine, at clinically relevant concentrations, can silence ectopic discharges in
injured nerves.16,53
Action at Calcium Channels
Synaptic transmission in the dorsal horn is triggered by calcium (Ca11) channel
opening, and Ca11 channels can propagate action potentials, as has been demon-
strated in heat nociceptive neurons in mammalian skin.54 Voltage-gated Ca11 chan-
nels closely resemble Na1 channels in structure and, not surprisingly, are blocked by
local anesthetics; although a greater concentration of local anesthetic is necessary
when compared with that needed for Na1 channel blockade.55
Action at Potassium Channels
Potassium (K1) channels are expressed in many areas of the nervous system and have
a role in neuronal plasticity. In peripheral neurons, K1 channels contribute to the decay
phase of the action potential and have a role in maintaining the resting membrane
potential. A specific K1 channel, Kv4.2, is thought to play a significant role in
Fig. 1. Mechanism of action of lidocaine for Na1 channel blockade. The nonionized form of
lidocaine crosses the axonal membrane and becomes ionized (protonated). The ionized
form binds to the cytoplasmic side of the Na1 channel, thereby blocking Na1 transfer across
the membrane.
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transmitting inflammatory pain in peripheral neurons and is important in neuronal plas-
ticity.56 Lidocaine blocks voltage-gated and voltage-independent K1 channels,
although the affinity of lidocaine for these channels is much less than its affinity for
Na1 channels.57
Inhibition of G Protein-Coupled Receptors
Lidocaine is known to inhibit G protein-coupled receptors (GPCRs), which make up
a large superfamily of transmembrane proteins that undergo conformational changes
after binding extracellular ligands, resulting in regulation of intracellular enzymes.58
These receptors respond to a variety of physical and chemical stimuli, neurotransmit-
ters, neuropeptides, hormones, and glycoproteins. Sensory neuron-specific GPCRs
are expressed exclusively on nociceptive neurons and are implicated in the modula-
tion of nociception.59 Lidocaine interacts with the signaling of GPCRs to modulate
K1 and Ca11 channel function.60
Activation of TRPV1 Receptors
The TRPV1 receptor is a nonselective cation channel that is expressed by sensory
neurons and in small-diameter DRG neurons, and was initially identified as the
receptor for capsaicin.61,62 It is now believed that these channels are sensory trans-
ducers that participate in the generation and modulation of nociception evoked by
chemical, thermal, and mechanical stimuli.
Lidocaine may activate and sensitize TRPV1, and this activation can contribute to
the release of neurotransmitters resulting in nociceptive modulation.63 There is also
evidence that TRPV1 and transient receptor potential ankyrin-1 receptors are coex-
pressed in small-diameter noxious sensory neurons (Ad and C-fibers),64 and their acti-
vation by systemic lidocaine modulates nociception.
Inhibition of NMDA Receptors
Hypersensitivity in either inflammatory or neuropathic pain is predominantly mediated
by N-methyl-D-aspartate (NMDA) receptors.65,66 At the spinal cord, lidocaine reduces
the postsynaptic depolarization mediated by NMDA receptors.67,68 Lidocaine’s inhibi-
tion of activated NMDA receptors in vitro is thought to be due to inhibition of protein
kinaseC (PKC).69 In rats, small concentrations of lidocaine inhibited the depolarizations
detected in spinal root recordings resulting from thedirect chemical activation ofNMDA
receptors.68,70 The wind-up phenomenon that contributes to central sensitization after
repeated or intense noxious stimulation is suppressed by lidocaine applied directly to
the spinal cord.71 Systemic administration of lidocaine suppressed neuronal activity,
including C-afferent fiber-evoked activity, in rat spinal cord.72
Anti-Inflammatory Effects
The anti-inflammatory effects of local anesthetics are another important mechanism
for their antinociceptive actions (see Box. 1). Inflammatory products, such as PGE2,
5-hydroxytryptamine, and adenosine, augment the excitability of neurons by
enhancing inward currents on Na1 channels expressed on primary afferent neurons.73
These changes result in peripheral and central sensitization. Interestingly, the effects
of lidocaine on inflammatory cells such as polymorphonuclear granulocytes (PMNs)
are not caused by Na1 channel blockade because Na1 channels are not expressed
on PMNs.74
Although there is ample evidence, from in vitro and in vivo studies, for the anti-
inflammatory properties of lidocaine, the molecular mechanism underlying these
anti-inflammatory effects are not well described. Proposed mechanisms include
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effects on cyclic adenosine monophosphate, GPCRs, nicotinamide adenine dinucle-
otide, Na1– H1 exchanger, and PKC.22 In lipopolysaccharide-stimulated macro-
phages, lidocaine significantly decreased inducible nitric oxide synthase expression
by suppression of nuclear factor kB activation.75 In human surgical patients, perioper-
ative lidocaine administration significantly decreased the ex vivo production of IL-1ra
and IL-6.76
Miscellaneous Effects of Lidocaine
Gamma-aminobutyric acid (GABA) and glycine are the main inhibitory neurotransmit-
ters in the CNS.77 There is ample evidence for the modulating effect of lidocaine on
glycine signaling. Indeed, it is suggested that lidocaine may exert some of its antino-
ciceptive activity through glycinergic pathways.63,78 Intravenous lidocaine activates
the strychnine-sensitive glycine receptors in WDR neurons in rats, resulting in inhibi-
tion of transmission of noxious and nonnoxious information.63 Excitation of GABAer-
gic/glycinergic inhibitory interneurons, via TRPV1 receptors, after IV administration of
lidocaine, may also have a role in suppression of WDR neuronal activities.63
Lidocaine can inhibit substance P binding to neural cells,79 neurokinin receptor-
mediated postsynaptic depolarizations,68 and glutamate-evoked activity in spinal
dorsal horn neurons.80
ANESTHETIC AND ANTINOCICEPTIVE EFFECTS OF LIDOCAINE IN THE HORSE
Systemically administered lidocaine has recently gained popularity in equine practice
for its volatile anesthetic sparing effects, its presumed antinociceptive actions, and for
treatment of ileus. However, to date, there are only a few studies of the effects of intra-
venously administered lidocaine in either anesthetized or conscious horses.
Anesthetic-Sparing Effects of Lidocaine
In an experimental setting, lidocaine decreased the minimum alveolar concentration
(MAC) of halothane in ponies.81 In clinical studies of horses undergoing surgery, lido-
caine alone82–84 and in combination with ketamine85 decreased the required end-tidal
concentration of isoflurane. Lidocaine combined with ketamine and morphine
decreased the end-tidal concentration of sevoflurane required to maintain a surgical
plane of anesthesia in horses.86 These findings are consistent with those of a study
in which lidocaine caused a dose-dependent decrease in the bispectral index in anes-
thetized horses.87
The mechanism by which lidocaine decreases the volatile anesthetic MAC is uncer-
tain, but is probably not simply due to its antinociceptive properties, and may involve
multiple receptor types (see Box 1) such as NMDA, GABAA, acetylcholine, and
glycine.88 The magnitude of MAC reduction with lidocaine in ponies is dose-depen-
dent.81 Small doses of lidocaine (eg, 0.05 mg/kg/min) reduce the MAC by about
20%,81 and this is consistentwith findings in clinical studies that used lidocaineat doses
no greater than 0.05 mg/kg/min.82,83 A greater dose of lidocaine (eg, 0.1 mg/kg/min)
reduces the MAC of a volatile anesthetic by at least 35%.81
In a surgical model, lidocaine (3.0 mg/kg) was administered IV to horses anesthe-
tized with xylazine and ketamine.89 In that study, there was no difference between
the lidocaine and saline treatments in regards to the number of supplementary injec-
tions of xylazine and ketamine needed to maintain a surgical plane of anesthesia.
However, the study could not be tightly controlled because the horses were not
weighed before anesthesia, thus drug doses had to be estimated. The study did not
evaluate the analgesic effect of lidocaine in the postoperative period.
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Adverse effects of lidocaine administration were not reported in any of the afore-
mentioned studies; nevertheless, there is evidence that the intraoperative administra-
tion of lidocaine may decrease the quality of recovery.90 However, in the authors’
experience, this effect can be readily overcome by decreasing the plasma concentra-
tion of lidocaine at the time of awakening by (1) stopping the infusion before the end of
surgery or (2) decreasing the infusion rate over time or (3) delaying the horse’s first
attempt to stand by inducing sedation.
Antinociceptive Effects of Lidocaine
The effects of intravenously administered lidocaine on electroencephalography (EEG)
parameters were investigated in anesthetized ponies.91 Under halothane anesthesia,
ponies were given a loading dose of lidocaine (5.0 mg/kg, [IV]) over 15 minutes and an
infusion of 0.1 mg/kg/min. Lidocaine administration abolished measured EEG
changes which are indicative of noxious stimulation during castration; based on these
findings, the authors concluded that lidocaine is antinociceptive.
In 2005, Robertson and colleagues92 investigated the antinociceptive effects of
systemically administered lidocaine in response to visceral and somatic stimuli in
conscious horses. Somatic antinociception was assessed using a thermal stimulus,
by applying a heat source over the withers. Visceral antinociception was evaluated
by the response to colorectal and duodenal distension. Lidocaine was administered
as a loading dose of 2.0 mg/kg over 20 minutes and a constant rate infusion (CRI)
of 0.05 mg/kg/min. The resulting plasma concentrations of lidocaine during delivery
of the noxious stimuli ranged from 0.7 to 1.2 mg/mL. Lidocaine treatment did not
have a significant effect on the response to colorectal or duodenal distension in the
horses of that study, which was surprising, given that lidocaine dose-dependently
inhibited cardiovascular responses to colorectal distension in rats.25 Lidocaine treat-
ment significantly increased the thermal threshold, and this was contrary to the find-
ings in studies using human volunteers, where systemic lidocaine has no effect on
thermal thresholds.93
Potential Role in Treating Laminitis-Induced Pain
There is a clinical report that intravenously administered lidocaine provided analgesia
in horses suffering from chronic laminitis.94 A recent study has demonstrated that the
histopathological changes in the sensory nerves innervating the forelimb of horses
suffering from chronic laminitis were consistent with those reported in previously char-
acterized neuropathic pain states.2 Thus, it seems plausible that systemic lidocaine,
which has been shown to be effective for the treatment of neuropathic pain,14,15 would
be beneficial in the treatment of laminitis.
OTHER POTENTIAL BENEFITS OF SYSTEMIC LIDOCAINE
Besides its anesthetic and antinociceptive effects, lidocaine has properties that make
its use desirable in the surgical patient, particularly in the horse undergoing abdominal
surgery.
Effect on the Incidence of Post-Operative Ileus
A number of studies with human patients have established that the perioperative use
of lidocaine reduces the duration of postoperative ileus (POI).13,23,95 The effect of intra-
operative administration of lidocaine on the incidence and severity of POI has not been
investigated widely in horses; however, in one study, the intraoperative administration
of lidocaine to surgical colic patients was thought to be associated with a reduction in
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the incidence of POI.96 In another study of horses undergoing abdominal surgery, the
intraoperative administration of lidocaine (0.025 mg/kg/min) combined with CRI of
0.05 mg/kg/min for 24 hours after surgery was considered to have a beneficial effect
on intestinal motility.97 In a study of horses with POI, the administration of lidocaine
postoperatively resulted in shorter hospitalization time.94
Effects on Ischemia-Reperfusion Injury
Systemic lidocaine decreases reperfusion injury following ischemia. In a myocardial
ischemia model in dogs, lidocaine reduced the size of the myocardial infarct.98 In an
ischemic jejunal model in horses, pretreatment with lidocaine decreased plasma
PGE2 metabolite concentration and mucosal cyclooxygenase 2 expression, and
ameliorated the effect of flunixin meglumine on promoting mucosal neutrophil
infiltration.99
Effects in Endotoxemic Animals
Lidocaine has been investigated for its therapeutic potential in various models of
endotoxemia in laboratory animals. In rabbits, lidocaine attenuated the hypotension
and metabolic acidosis consequent to the endotoxin administration.100 In rats, lido-
caine attenuated endotoxin-induced changes in leukocyte adhesion to endothelial
cells and preserved endothelial integrity, as demonstrated by a decrease in macromo-
lecular leakage.101
METABOLISM AND ELIMINATION OF LIDOCAINE
Metabolism of lidocaine in the horse produces monoethylglycinexylidide and glycinex-
ylidide, which are the pharmacologically active metabolites81 that are de-ethylation
products of lidocaine also produced in the human liver via the cytochrome P450
superfamily of enzymes. Thus, lidocaine may be considered to undergo metabolism
via the cytochrome P450 system in horses. Lidocaine and its metabolites are excreted
in the urine. Feary and colleagues102 compared lidocaine kinetics in conscious horses
and horses anesthetized with sevoflurane, and concluded that general anesthesia
changes lidocaine kinetics. Plasma lidocaine concentrations were increased at all
times in the anesthetized group, and this was attributed to a decrease in the volume
of distribution and clearance of lidocaine. Lidocaine clearance is greatly dependent
on hepatic blood flow,103 and a decrease in hepatic blood flow, such as may occur
during sevoflurane anesthesia, will decrease lidocaine clearance. Additionally, anes-
thetic drugs metabolized by the cytochrome P450 system may compete for binding
sites and delay clearance.
CONTRAINDICATIONS TO SYSTEMIC ADMINISTRATION OF LIDOCAINE
Because of lidocaine’s effects on inflammation and phagocytic cell function, there has
been concern that inhibiting these functions might increase the incidence of bacterial
infections. It appears, however, that the residual polymorphonuclear cell function is
adequate and the bactericidal effect of PMNs from human patients being adminis-
tered lidocaine infusions is only slightly decreased.104 Nevertheless, in a study of
rats inoculated with Staphylococcus aureus, five of six rats treated with systemic lido-
caine died, whereas only one of six rats in the control group died.105 Thus, it may be
prudent to avoid the use of systemic lidocaine in patients with gross bacterial contam-
ination. Paradoxically, lidocaine has anti-bacterial effects; however, these effects
occur at concentrations greater that what can be safely achieved with systemic
administration.106
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RECOMMENDATIONS FOR THE USE OF SYSTEMIC LIDOCAINE
Intraoperative Administration of Lidocaine
Based on currently available data from horses and other species, intraoperative
administration of lidocaine is expected to decrease the volatile anesthetic MAC, post-
operative pain, the incidence and severity of postoperative ileus, and inflammation.
In the authors’ hospital, lidocaine is used with isoflurane, ketamine, and xylazine as
part of a multimodal anesthetic regimen. After sedation with xylazine hydrochloride
and induction of anesthesia with ketamine and diazepam, a loading dose of lidocaine
(3.0 mg/kg over 15minutes) is given and a CRI of 0.1 mg/kg/min is administered during
the first hour. The CRI is decreased to 0.075 and 0.05 mg/kg/min for the second and
third hours, respectively. Concurrently, the end-tidal concentration of isoflurane is
maintained at 0.4% to 0.6%, and ketamine (2.5 mg/kg/hr) and xylazine (0.25 mg/kg/hr)
are infused. The lidocaine infusion is generally stopped approximately 20 minutes
before the end of surgery. To delay time to first movement, horses are sedated with
romifidine (0.04 mg/kg) and ketamine (0.3 mg/kg) when placed in the recovery box.
Problems that can be attributed to lidocaine administration have not been encountered
while using this technique in approximately 2,000 horses.
Lidocaine Administration to Conscious Horses
Systemic lidocaine may be safely used in the conscious horse; however, in this
scenario, careful attention must be given to the loading dose and infusion rate. A
loading dose of lidocaine (1.3–1.5 mg/kg) is administered over 3 to 5 minutes, and
this is followed by a CRI of 0.05 mg/kg/min. Lidocaine can be safely administered
at this rate for many hours, and adverse effects, when they occur, are generally due
to an unintentional increase in the infusion rate.
SIGNS AND TREATMENT OF LIDOCAINE TOXICITY
Lidocaine toxicity produces a concentration-dependent spectrum of effects (Fig. 2)
that are manifested primarily at the central nervous and cardiovascular systems,
although cardiac signs of toxicity occur at much greater plasma concentrations.44
Fig. 2. Clinical signs of lidocaine toxicity. The arrow indicates increasing plasma concentra-
tions of lidocaine. These signs may not necessarily occur as a continuum in all horses.
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Because of the relatively large volumes of lidocaine required to produce toxicity in an
adult horse, toxicity is unlikely to happen under normal circumstances. Treatment of
severe lidocaine toxicity may be unrewarding, thus emphasized the importance of vigi-
lance during lidocaine administration.
CNS Toxicity
Signs of CNS toxicity in conscious horses are initially manifested as eyelid blinking,
nystagmus, muscle twitching and ataxia, and the horse may assume sternal recum-
bency.107 Some horses have signs of visual dysfunction,107 which is consistent with
reported effects of visual impairment with lidocaine toxicity in human patients.44 These
signs usually resolve fairly quickly once the lidocaine infusion is stopped. However,
treatment with a sedative (eg, xylazine, 0.3 mg/kg, IV) or an anticonvulsant (eg, diaz-
epam, 0.05 mg/kg, IV) may be indicated if CNS signs persist beyond a few minutes. In
severe overdosing, the aforementioned signs may progress to seizures, unconscious-
ness, and respiratory arrest. Paradoxically, lidocaine has been shown to suppress
seizures at plasma concentrations less than 5.0 mg/mL,108 and has been used
successfully for the treatment of status epilepticus in children.109
Treatment of seizures should begin quickly and, in addition to sedatives and anti-
convulsants, general anesthesia may be necessary in some cases to control the
seizures. Although a GABA agonist, such as thiopental or propofol, may be the ideal
agent to induce anesthesia; ketamine combined with a benzodiazepine is probably
satisfactory if the horse is heavily sedated (eg, xylazine 1.0 mg/kg, IV) because ket-
amine significantly prevented lidocaine-induced generalized tonic-clonic seizures in
mice.110 Guaifenesin, a central muscle relaxant, should be beneficial in decreasing
the skeletal muscle manifestations of toxicity. Provision of supplemental oxygen is
indicated because of the increase in oxygen demands in the brain and muscle;
hypoxemia further exacerbates lidocaine toxicity.
Cardiovascular System Toxicity
Toxicity of the cardiovascular system occurs at plasma lidocaine concentrations much
greater than those necessary to cause seizures44; thus, cardiovascular depression is
less likely to occur during lidocaine administration to horses. In conscious horses,
plasma concentrations of lidocaine between 1.85 and 4.53 mg/mL caused statistically
significant changes in P-wave duration, P-R interval, R-R interval, and Q-T interval;
however, these changes were within the normal reference ranges, and were not
deemed to be clinically significant.107 Nevertheless, lidocaine toxicity can result in
hypotension, myocardial depression, and refractory cardiac dysrhythmias. We have
observed severe hypotension in an experimental setting where a large dose of lido-
caine (5.0 mg/kg IV) was administered over a 5-minute period to ponies anesthetized
with halothane. Although hypotension was readily reversed by infusion of dobutamine
in those ponies, severe lidocaine-induced cardiovascular depression may, in some
cases, be resistant to conventional treatment with anticholinergic drugs and positive
inotropes.
SUMMARY
The antinociceptive effects of systemic lidocaine are well documented in human
beings and laboratory animals. There are few studies evaluating the efficacy of
systemic lidocaine in horses; however, evidence exists for its anesthetic and antinoci-
ceptive effects in this species. Based on findings from the study of human patients, it
appears that the best results are obtained when lidocaine is administered in the
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perioperative period, rather than in the postoperative period only. Administration of
lidocaine intraoperatively has the benefit of decreasing volatile anesthetic MAC and
the potential to provide postoperative analgesia and decrease the incidence of post-
operative ileus.
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